Strategies for clinical trials in type 1 diabetes

Journal of Autoimmunity

Volumn 71, Issue , 2016, Pages 88-96

  Ehlers, Mario R ^a  

^a Immune Tolerance Network   (United States)

Author keywords

Adaptive trials; Combination therapies; Immune tolerance network; New onset T1D; Responder analysis; cell

Indexed keywords

ABATACEPT; RITUXIMAB; TEPLIZUMAB; AUTOANTIGEN;

CLINICAL TRIAL (TOPIC); FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GLYCEMIC CONTROL; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; LYMPHOCYTE SUBPOPULATION; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

AUTOANTIGENS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; RESEARCH DESIGN; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84962441569     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.03.008     Document Type: Review

References (83)

1. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
2. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32:457-467.
3. Klein B.E.K., Klein R. Further insight on the limits of success of glycemic control in type 1 diabetes. Diabetes 2015, 64:341-343.
4. Farrington C. The artificial pancreas: challenges and opportunities. Lancet Diabetes Endocrinol. 2015, 3:937.
5. Lind M., Svensson A.M., Kosiborod M., Gudbjörnsdottir S., Pivodic A., Wedel H., et al. Glycemic control and excess mortality in type 1 diabetes. N. Engl. J. Med. 2014, 371:1972-1982.
6. Herold K.C., Vignali D.A.A., Cooke A., Bluestone J.A. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 2013, 13:243-256.
7. Ehlers M.R. Immune interventions to preserve β cell function in type 1 diabetes. J. Investig. Med. 2016, 64:7-13.
8. Smilek D.E., Ehlers M.R., Nepom G.T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis. Mod. Mech. 2014, 7:503-513.
9. Insel R.A., Dunne J.L., Atkinson M.A., Chiang J.L., Dabelea D., Gottlieb P.A., et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015, 38:1964-1974.
10. Ehlers M.R., Nepom G.T. Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev. Diabetes Stud. 2012, 9:359-371.
11. Greenbaum C.J., Harrison L.C. Immunology of Diabetes Society, Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003, 52:1059-1065.
12. Simon R., Freedman L.S. Bayesian design and analysis of two × two factorial clinical trials. Biometrics 1997, 53:456-464.
13. Rigby M.R., Harris K.M., Pinckney A., DiMeglio L.A., Rendell M.S., Felner E.I., et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Investig. 2015, 125:3285-3296.
14. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
15. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
16. Simon R.M., Steinberg S.M., Hamilton M., Hildesheim A., Khleif S., Kwak L.W., et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 2001, 19:1848-1854.
17. McAlister F.A., Straus S.E., Sackett D.L., Altman D.G. Analysis and reporting of factorial trials. A systematic review. JAMA 2003, 289:2545-2553.
18. Greenbaum C.J., Beam C.A., Boulware D., Gitelman S.E., Gottlieb P.A., Herold K.C., et al. Fall in C-peptide during first 2 years from diagnosis. Evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012, 61:2066-2073.
19. Jones D. Adaptive trials receive boost. Nat. Rev. Drug Disc. 2010, 9:345-348.
20. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
21. Klatzmann D., Abbas A.K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 2015, 15:283-294.
22. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
23. Hartemann A., Bensimon G., Payan C.A., Jacqueminet S., Bourron O., Nicolas N., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1:295-305.
24. Waldron-Lynch F., Kareclas P., Irons K., Walker N.M., Mander A., Wicker L.S., et al. Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open 2014, 4:e005559.
25. Truman L.A., Pekalski M.L., Kareclas P., Evangelou M., Walker N.M., Howlett J., et al. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. BMJ Open 2015, 5:e009799.
26. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
27. Hagopian W., Ferry R.J., Sherry N., Carlin D., Bonvini E., Johnson S., et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes. Two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013, 62:3901-3908.
28. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
29. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
30. Rigby M.R., DiMeglio L.A., Rendell M.S., Felner E.I., Dostou J.M., Gitelman S.E., et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013, 1:284-294.
31. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann. Intern. Med. 1998, 128:517-523. Diabetes Control and Complications Trial Research Group.
32. Freckmann G., Hagenlocher S., Baumstark A., Jendrike N., Gillen R.C., Rössner K., et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J. Diabetes Sci. Technol. 2007, 1:695-703.
33. Xing D., Kollman C., Beck R.W., Tamborlane W.V., Laffel L., Buckingham B.A., et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol. Ther. 2011, 13:351-358.
34. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J. Clin. Endocrinol. Metab. 1987, 65:30-36. DCCT Research Group.
35. Palmer J.P., Fleming G.A., Greenbaum C.J., Herold K.C., Jansa L.D., Kolb H., et al. C-Peptide Is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Report of an ADA workshop, 21-22 October 2001. Diabetes 2004, 53:250-264.
36. Greenbaum C.J., Mandrup-Poulsen T., Friedenberg McGee P., Battelino T., Haastert B., Ludvigsson J., et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008, 31:1966-1971.
37. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
38. Lachin J.M., McGee P., Palmer J.P. DCCT/EDIC research group, impact of c-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes 2014, 63:739-748.
39. Akirava E.M., Lebastchia J., Galvana E.M., Henegariua O., Akiravb M., Ablamunitsa V., et al. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19018-19023.
40. Lebastchi J., et al. Immune therapy and β-cell death in type 1 diabetes. Diabetes 2013, 62:1676-1680.
41. Husseiny M.I., Kaye A., Zebadua E., Kandeel F., Ferreri K. Tissue-specific methylation of human insulin gene and PCR assay for monitoring beta cell death. PLoS One 2014, 9:e94591.
42. Herold K.C., Usmani-Brown S., Ghazi T., Lebastchi J., Beam C.A., Bellin M.D., et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J. Clin. Investig. 2015, 125:1163-1173.
43. Fisher M.M., Watkins R.A., Blum J., Evans-Molina C., Chalasani N., DiMeglio L.A., et al. Elevations in circulating methylated and unmethylated preproinsulin DNA in new-onset type 1 diabetes. Diabetes 2015, 64:3867-3872.
44. Özcan S. Minireview: microRNA function in pancreatic β cells. Mol. Endocrinol. 2014, 28:1922-1933.
45. Erener S., Mojibian M., Fox J.K., Denroche H.C., Kieffer T.J. Circulating miR-375 as a biomarker of β-cell death and diabetes in mice. Endocrinology 2013, 154:603-608.
46. Imagawa A., Hanafusa T., Tamura S., Moriwaki M., Itoh N., Yamamoto K., et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes. Close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001, 50:1269-1273.
47. Richardson S.J., Morgan N.G., Foulis A.K. Pancreatic pathology in type 1 diabetes mellitus. Endocr. Pathol. 2014, 25:80-92.
48. Krogvold L., Edwin B., Buanes T., Ludvigsson J., Korsgren O., Hyöty H., et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 2014, 57:841-843.
49. Hanafusa T., Imagawa A. Insulitis in human type 1 diabetes. Ann. N.Y. Acad. Sci. 2008, 1150:297-299.
50. Laurent D., Vinet L., Lamprianou S., Daval M., Filhoulaud G., Ktorza A., et al. Pancreatic β-cell imaging in humans: fiction or option?. Diabetes Obes. Metab. 2016, 18:6-15.
51. 18F-fluoropropyl-dihydrotetrabenazine and PET. J. Nucl. Med. 2012, 53:908-916.
52. 111In-labelled exendin. Diabetologia 2014, 57:950-959.
53. Denis M.C., Mahmood U., Benoist C., Mathis D., Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12634-12639.
54. Turvey S.E., Swart E., Denis M.C., Mahmood U., Benoist C., Weissleder R., et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J. Clin. Investig. 2005, 115:2454-2461.
55. Gaglia J.L., Guimaraes A.R., Harisinghani M., Turvey S.E., Jackson R., Benoist C., et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. Investig. 2011, 121:442-445.
56. Gaglia J.L., Harisinghani M., Aganj I., Wojtkiewicz G.R., Hedgire S., Benoist C., et al. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:2139-2144.
57. Ehlers M.R., Rigby M.R. Targeting memory T cells in type 1 diabetes. Curr. Diabetes Rep. 2015, 15:84.
58. Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat. Rev. Immunol. 2012, 12:191-200.
59. Orban T., Beam C.A., Xu P., Moore K., Jiang Q., Deng J., et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 2014, 63:3449-3457.
60. Herold K.C., Gitelman S.E., Willi S.M., Gottlieb P.A., Waldron-Lynch F., Devine L., et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013, 56:391-400.
61. Tooley J.E., Vudattu N., Choi J., Cotsapas C., Devine L., Raddassi K., et al. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur. J. Immunol. 2016, 46:230-241.
62. Ermann J., Rao D.A., Teslovich N.C., Brenner M.B., Raychaudhuri S. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat. Rev. Rheum. 2015, 11:541-551.
63. Odegard J.M., Nepom G.T., Wambre E. Biomarkers for antigen immunotherapy in allergy and type 1 diabetes. Clin. Immunol. 2015, 161:44-50.
64. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210.
65. Bacher P., Schink C., Teutschbein J., Kniemeyer O., Assenmacher M., Brakhage A.A., et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J. Immunol. 2013, 190:3967-3976.
66. Wambre E., James E.A., Kwok W.W. Characterization of CD4+ T cell subsets in allergy. Curr. Opin. Immunol. 2012, 24:700-706.
67. + regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 2010, 10:849-859.
68. + regulatory T cells. J. Immunol. 2008, 181:7350-7355.
69. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 2008, 154:353-359.
70. + T cells in type 1 diabetes. Sci. Transl. Med. 2013, 5. 191ra82.
71. Youngblood B., Hale J.S., Ahmed R. T-cell memory differentiation: insights from transcriptional signatures and epigenetics. Immunology 2013, 139:277-284.
72. Vahedi G., Kanno Y., Sartorelli V., O'Shea J.J. Transcription factors and CD4 T cells seeking identity: masters, minions, setters and spikers. Immunology 2013, 139:294-298.
73. Spreafico R., Rossetti M., van den Broek T., Jansen N.J.G., Zhang H., Moshref M., et al. A sensitive protocol for FOXP3 epigenetic analysis in scarce human samples. Eur. J. Immunol. 2014, 44:3141-3143.
74. Gitelman S.E., Gottlieb P.A., Rigby M.R., Felner E.I., Willi S.M., Fisher L.K., et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013, 1:306-316.
75. DuPage M., Chopra G., Quiros J., Rosenthal W.L., Morar M.M., Holohan D., et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 2015, 42:227-238.
76. Nepom G.T., Ehlers M., Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin. Immunol. 2013, 149:279-285.
77. Marioni J.C., Mason C.E., Mane S.M., Stephens M., Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008, 18:1509-1517.
78. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 2008, 5:621-628.
79. Xu X., Zhang Y., Williams J., Antoniou E., McCombie W.R., Wu S. Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT-29 colon cancer cells and simulated datasets. BMC Bioinf. 2013, 14:S1.
80. Geiss G.K., Bumgarner R.E., Birditt B., Dahl T., Dowidar N., Dunaway D.L. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotech. 2008, 26:317-325.
81. Wherrett D.K., Chiang J.L., Delamater A.M., DiMeglio L.A., Gitelman S.E., Gottlieb P.A., et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care 2015, 38:1975-1985.
82. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
83. Beam C.A., Gitelman S.E., Palmer J.P. Type 1 Diabetes TrialNet Study Group, Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes 2014, 63:3120-3127.